Log In
Print
BCIQ
Print
Print this Print this
 

Synagis, palivizumab (MEDI-493)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionHumanized mAb against respiratory syncytial virus (RSV)
Molecular Target RSV F protein
Mechanism of ActionBinds RSV F protein
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevent and treat respiratory syncytial virus (RSV); Prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV); Prevent respiratory syncytial virus (RSV) disease in pediatric patients; Prevent respiratory syncytial virus (RSV) disease in premature infants; Prevent respiratory syncytial virus (RSV) in high-risk pediatric patients; Prevent respiratory syncytial virus (RSV) infection; Treat and prevent respiratory syncytial virus (RSV) disease in hematopoietic stem cell transplant (HSCT) patients; Treat respiratory syncytial virus (RSV) disease; Treat respiratory syncytial virus (RSV) infection in high-risk infants; Treat respiratory syncytial virus (RSV) infection in infants
Regulatory Designation

Partner

AbbVie Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today